Inbiomotion is developing a unique single-gene-based biomarker, the MAF Test®, for the personalized adjuvant treatment of early-stage breast cancer patients
Inbiomotion is developing a unique single-gene-based biomarker, the MAF Test®, for the personalized adjuvant treatment of early-stage breast cancer patients. The test aims to improve patient selection for adjuvant bisphosphonate therapy, potentially reducing the risk of metastasis and improving overall survival.